England
| Name | Miles | Days Ridden | Trips |
|---|---|---|---|
| Cassie Pratley | 57 | 5 | 8 |
| Hamish Bettany | 6.5 | 1 | 1 |
| Matt Kirk | 2.2 | 1 | 1 |
| Adam Titi | 0 | 0 | 0 |
| Alastair Roberts | 0 | 0 | 0 |
| Name | Riders in challenge | Participation | Trips |
|---|---|---|---|
| Biopharm R&D | 1 | 33% | 1 |
| Product Development | 1 | 2% | 8 |
| BPR | 0 | 0% | 0 |
| GAC | 0 | 0% | 0 |
| Biopharm Innovation | 0 | 0% | 0 |
| Respiratory | 0 | 0% | 0 |
| Name | Department | Last login | ||
|---|---|---|---|---|
| Benjamin Griffith | SFC (UK) | over 1 year | Message | |
| Simon Hicks | SFC (UK) | 25 days | Message | |
| Nick Barton | Medicine Design | 4 months | Message | |
| David Dixon | Medicine Design | 8 months | Message | |
| Steven Howe | CGT | 8 months | Message | |
| Emma Koppe | 9 months | Message | ||
| Steve Thomas | SFC (UK) | over 1 year | Message | |
| Gary Finka | BPR | over 1 year | Message | |
| Shane Wodzynski | WREF | almost 2 years | Message | |
| Simon Knee | 2 years | Message |
| Name | staff | Riders | Distance (miles) | Trips | Transport Trips |
|---|---|---|---|---|---|
| CMC Analytical | 100 | 0 | 0 | 0 | 0 |
| PSDE | 50 | 1 | 104 | 32 | 0 |
| PTS-DDS | 250 | 1 | 186 | 19 | 10 |
| AS | 100 | 1 | 69 | 3 | 2 |
| CSci | 400 | 0 | 0 | 0 | 0 |
| BPR | 3 | 3 | 6696 | 366 | 99 |
| GAC | 50 | 2 | 1188 | 44 | 5 |
| Biopharm Innovation | 50 | 1 | 4 | 1 | 1 |
| Respiratory | 30 | 6 | 8662 | 686 | 318 |
| Respiratory | 30 | 3 | 2699 | 221 | 66 |
| DMS | 12 | 0 | 0 | 0 | 0 |
| R&D S&P | 12 | 2 | 20 | 7 | 5 |
| ATD | 40 | 3 | 76 | 8 | 8 |
| AIML | 15 | 0 | 0 | 0 | 0 |
| Emcor Engineering | 120 | 0 | 0 | 0 | 0 |
| SM Tech | 50 | 0 | 0 | 0 | 0 |
| CGT | 400 | 6 | 7903 | 849 | 399 |
| AIRU | 120 | 3 | 1695 | 109 | 93 |
| Bioimaging | 30 | 2 | 1038 | 114 | 34 |
| QPPV Office | 8 | 0 | 0 | 0 | 0 |
| CDQA | 30 | 0 | 0 | 0 | 0 |
| Epinova | 100 | 2 | 1189 | 346 | 144 |
| GDS | 3 | 0 | 0 | 0 | 0 |
| LAS | 60 | 0 | 0 | 0 | 0 |
| Product Development | 50 | 4 | 17665 | 643 | 199 |
| TSci | 200 | 1 | 6 | 1 | 1 |
| CPEM Biomarkers | 9 | 1 | 130 | 25 | 0 |
| SFC (UK) | 48 | 7 | 18701 | 1484 | 436 |
| Biopharm R&D | 3 | 2 | 7501 | 337 | 49 |
| ComputationalBiology | 40 | 1 | 1066 | 66 | 1 |
| RMA | 15 | 0 | 0 | 0 | 0 |
| BSci | 80 | 0 | 0 | 0 | 0 |
| SEMA QA | 3 | 0 | 0 | 0 | 0 |
| Data & Computational Science | 400 | 5 | 4726 | 280 | 17 |
| Drug Substance and Product Analysis | 100 | 1 | 1813 | 95 | 49 |
| CPEM Discovery Medicine | 15 | 2 | 33 | 7 | 1 |
| IVSD | 20 | 1 | 5 | 2 | 2 |
| BIB | 12 | 1 | 4934 | 346 | 39 |
| Medicine Design | 600 | 6 | 22720 | 1607 | 1023 |
| WREF | 200 | 3 | 12869 | 2787 | 2242 |
| Strategy Portfolio & Operations | 3 | 0 | 0 | 0 | 0 |
| Discovery DMPK | 25 | 1 | 163 | 40 | 40 |
| C3 | 20 | 1 | 8 | 4 | 4 |
| SPMB | 60 | 1 | 1328 | 51 | 8 |
| GSK Tech | 50 | 2 | 1443 | 102 | 15 |
| Tech Stewards | 8 | 1 | 6 | 1 | 1 |
| Biostatistics | 100 | 1 | 1 | 1 | 0 |
| IBPS | 3 | 1 | 20 | 1 | 0 |
| This can be deleted. | 1 | 0 | 0 | 0 | 0 |
